Management of Dry Eye Disease
For dry eye disease, begin with preservative-free artificial tears (more than 4 times daily), environmental modifications, and lid hygiene, then escalate to anti-inflammatory therapy with topical cyclosporine 0.05% or lifitegrast 5% for moderate disease, reserving punctal occlusion, autologous serum, and surgical interventions for severe refractory cases 1.
Stepwise Treatment Algorithm
Mild Dry Eye
Start with these foundational interventions:
- Preservative-free artificial tears are essential when using drops more than 4 times daily to avoid preservative toxicity 1. For less frequent use, preserved tears are acceptable.
- Environmental modifications: Lower computer screens below eye level to reduce lid aperture, use moisture chamber goggles, humidify ambient air, avoid air drafts with side shields on glasses, and schedule regular breaks during screen time 1.
- Treat contributing factors: Address blepharitis, meibomian gland dysfunction, trichiasis, or eyelid malposition (lagophthalmos, entropion/ectropion) 1.
- Emulsions, gels, and ointments provide longer-lasting effects but may blur vision—use thicker agents at bedtime 1, 2.
Common pitfall: Using preserved artificial tears frequently causes additional ocular surface toxicity. Switch to preservative-free formulations early.
Moderate Dry Eye
Add anti-inflammatory therapy to the above measures:
Topical cyclosporine 0.05% twice daily is FDA-approved and demonstrated a 10-mm increase in Schirmer test results in 15% of patients versus 5% with vehicle at 6 months 1. Ocular burning occurs in 17% of patients but is generally well-tolerated. After one year of twice-daily therapy, some patients can reduce to once daily without losing benefit. Evidence from a 2019 Cochrane review (30 trials, 4,009 participants) shows inconsistent effects on symptoms and tear film parameters, though it may increase conjunctival goblet cells 1.
Lifitegrast 5% ophthalmic solution was FDA-approved in 2016 as an alternative anti-inflammatory option 1.
Short-term topical corticosteroids can be used initially, then transition to cyclosporine for long-term management 3. Low-dose steroids long-term are reserved for patients with autoimmune diseases or moderate-to-severe DED 3.
Important nuance: While cyclosporine shows disease-modifying potential, the evidence for symptom improvement remains inconsistent. However, it remains a guideline-recommended option for moderate disease.
Severe Dry Eye
Escalate to these advanced interventions:
Punctal occlusion: Start conservatively with one punctum per eye per session using temporary plugs before considering permanent cautery occlusion 1.
Autologous serum 20% or autologous plasma rich in growth factors improves symptoms and corneal/conjunctival staining in Sjögren's syndrome and graft-versus-host disease patients 1. Allogeneic serum is an effective alternative when repeated blood sampling isn't feasible 1.
Oral cholinergic agonists for combined dry eye and dry mouth (Sjögren's syndrome):
- Cevimeline (FDA-approved) improves ocular irritation symptoms and tear production with fewer systemic side effects than pilocarpine 1
- Pilocarpine 5 mg orally four times daily improves reading focus and blurred vision but not light sensitivity or ocular discomfort; excessive sweating occurs in over 40% of patients, causing 2% to withdraw 1
Rigid gas-permeable scleral lenses have been successfully used for years but are limited by fitting difficulties, cost, and patient ability to manage insertion/removal 1.
Amniotic membrane grafts (self-retaining or sutureless) for refractory cases, though effects are short-term 1. Combined with contact lenses is superior to membrane alone 3.
Limited tarsorrhaphy decreases tear film instability in severe cases unresponsive to other therapies 1.
Special Considerations
Filamentary keratitis: Debride filaments with moistened cotton-tip applicator or forceps, apply N-acetylcysteine 10% to decrease mucus viscosity, consider soft contact lenses (but use cautiously with neurotrophic keratopathy due to infection risk) 1.
Meibomian gland dysfunction: Treat with warm compresses, in-office thermal devices, intense pulsed light therapy, low-level light therapy, lid wipes, anti-Demodex therapies, blepharoexfoliation, and topical antibiotics 4, 5.
Stronger corticosteroids (betamethasone) for longer duration in autoimmune disease or moderate-to-severe DED 3.
When to Refer to Ophthalmology
Patients require ophthalmologist evaluation for 1:
- Moderate or severe pain
- Lack of response to therapy
- Corneal infiltration or ulceration
- Progressive conjunctival scarring
- Vision loss
Follow-Up Strategy
Frequency depends on disease severity and therapeutic response. Patients with sterile corneal ulceration may require daily follow-up 1. The purpose is to assess treatment response, monitor for ocular surface damage, and adjust therapy accordingly.
Critical point: DED management requires addressing all etiologic components with both pharmacologic and nonpharmacologic interventions for long-term success 4, 6.